Pressemitteilung BoxID: 650314 (aap Implantate AG)
  • aap Implantate AG
  • Lorenzweg 5
  • 12099 Berlin
  • Ansprechpartner
  • Marc Heydrich
  • +49 (30) 75019-134

aap reports record sales of EUR 11.6 million in the fourth quarter of 2013; Full year 2013 sales of EUR 40 million

(PresseBox) (Berlin, ) aap Implantate AG (XETRA: AAQ.DE) generated in the fourth quarter of 2013 sales of EUR 11.6 million (previous year: EUR 8.9 million) according to preliminary figures, representing a 30% year-on-year increase. In the full financial year of 2013, aap increased its sales by 10% on the previous year from EUR 36.4 million to EUR 40.0 million. EBITDA for the fourth quarter 2013 is reconfirmed be between EUR 1.3 million and EUR 1.7 million and therefore result in a total EBITDA of approx. EUR 7.0 million for the financial year 2013. With 10% sales growth EBITDA rose by around 15% on the previous year (2012: EBITDA EUR 6.1 million), clearly reflecting consistent implementation of the profitable growth strategy.

2013 - Results and Analysis

Full-year 2013 sales totalled EUR 40.0 million (previous year: EUR 36.4 million), amounting to a 10% year-on-year sales growth. Sales growth in the financial year of 2013 was achieved mainly in the two core business areas Trauma and Biomaterials as well as by the exclusive license agreement and the development and supply agreement which were signed in the first quarter of 2013. The contract manufacturing business (EMCM B.V.) for gels, liquids and bone materials in Nijmegen, Netherlands, also reported solid growth.

2014 - Outlook

In the financial year of 2014, aap will concentrate on the further optimisation in the areas of customers, innovation, finance and organisation that we will specify in our Management Agenda for 2014.

Forward-looking statement

This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

aap Implantate AG

aap is a global medical device company headquartered in Berlin, Germany that develops, manufactures and markets innovative biomaterials and implants that are used in orthopedic procedures. The Company's products, which include a full line of plating systems, cannulated screws and bone cement products, are primarily used in the orthopedic specialty areas of trauma and spine repair. The Company's products are sold through its direct sales force, distribution partners and license agreements with OEM partners. aap's stock is listed in the Prime Standard segment of the Frankfurt Stock Exchange. For more information, please visit, or download the Company's investor relations app from the Apple's App Store or Google Play.

Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an